SEC Form 4											
FORM 4		UNITE	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549						OMB APPROVAL		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).		STA	STATEMENT OF CHANGES IN BENEFICIAL OWNE Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940					RSHIP OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Addres <u>Rajangam Ka</u>	on <sup>*</sup>		2. Issuer Name <b>and</b> Ticker or Trading Symbol Senti Biosciences, Inc. [SNTI]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) C/O SENTI BIOSCIENCES, INC.		(Middle)		3. Date of Earliest Transaction (Month/Day/Year)				Officer (give title below) Chief Medic			
2 CORPORATE DRIVE FIRST FLOOR			4. If An	4. If Amendment, Date of Original Filed (Month/Day/Year)				6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person			
(Street) SOUTH SAN	СА	94080					X		ne Reporting Pers		
FRANCISCO			Rule	Rule 10b5-1(c) Transaction Indication							
(City)	(State)	(Zip)		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							
		Table I - No	n-Derivative S	ecurities Acq	uired, Disp	oosed of, or Benefi	cially C	Dwned			
			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	

Code V

Α

6. Date Exercisable and

Expiration Date (Month/Day/Year)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Date

1. The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Senti Biosciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. All of the shares underlying the award vest in three substantially equal annual installments over three years from February 1, 2024, subject to the reporting person's continued service

2. The shares underlying this option vest in 48 substantially equal monthly installments over four years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date.

Exercisable

(2)

(D)

5. Number of

Acquired (A)

or Disposed of (D) (Instr. 3, 4 and 5)

(A)

152.000

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Derivative Securities

02/01/2024

Transaction Code (Instr. 8)

۷

Code

Α

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Common Stock

2. Conversion

or Exercise Price of

Derivative

\$0,46

Explanation of Responses:

through the applicable vesting date.

Security

3. Transaction

(Month/Day/Year)

02/01/2024

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

Date

3A. Deemed

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Execution Date

if any (Month/Day/Year)

1. Title of

Derivative

Security (Instr. 3)

Stock Option

Buy)

(Right to

Remarks:

(A) or (D)

A

7. Title and Amount

of Securities Underlying Derivative Security

Amount

or Number

of Shares

152,000

/s/ Mike Rhee, attorney-in-fact

\*\* Signature of Reporting Person

(Instr. 3 and 4)

Title

Commo

Stock

Price

**\$**0

Amount

Expiration Date

01/31/2034

101,000(1)

Transaction(s) (Instr. 3 and 4)

8. Price of

Derivative

Security (Instr. 5)

**\$**0

101,000

9. Number of

derivative Securities Beneficially

Following Reported Transaction(s)

152,000

02/02/2024

Date

Owned

(Instr. 4)

D

10.

Ownership

Form: Direct (D)

or Indirect (I) (Instr. 4)

D

11. Nature

of Indirect

Beneficial

(Instr. 4)

Ownership